NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

That trial is unclear to me. I am open to more information but they are giving the vaccine pre-surgery in Cohort 1 Arm A. That can’t therefore be a lysate based vaccine. Plus the vaccine targets H3 G34 mutation. I don’t think that is DCVax-L. It’s possible that patients receiving after surgery vaccination are receiving a lysate based vaccine, but it does not say that and seems unlikely they’d receive different vaccines in the same trial.

This trial is for a less mutated non-GBM tumor type. They are targeting the indicated mutation. Plus I do not see any reason to change the normal references to DCVax-L previously used by UCLA in their own non-sponsored trials, which would be ATL-DC.

Don’t mean to upset anyone, but I think people are taking others down a few rabbit holes these days in some sort of anxious effort to manufacture news while we wait for actual news. That can be dangerous to real shareholders and disruptive to sentiment, long-term by creating all kinds of anticipation then disappointment that have nothing to do with reality.

Here is another link.

https://trials.braintumor.org/trials/NCT05457959